Publications

Recent Declines in Beta-Lactam and MLS_B Resistances Among S. pneumoniae and Age-Related Effects: Report from the SENTRY Antimicrobial Surveillance Program (North America [NA], 1997 – 2002), Lead author: Jones RN, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Penicillin and Macrolides Resistance Trends among Streptococcus pneumoniae Isolated in Latin America between 1998 and 2002: Report of SENTRY Antimicrobial Surveillance Program, Lead author: Andrade SS, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

In Vitro Activity of Garenoxacin, a Novel Des-F(6)-Quinolone, Against 120,088 Clinical Isolates Collected Worldwide by the SENTRY Antimicrobial Surveillance Program (1999-2002), Lead author: Sader HS, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Activity of AZD2563 and Comparator Agents Tested Against 6,444 Staphylococci, Streptococci and Enterococci (North America, 2001 – 2002), Lead author: Fritsche TR, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

In Vitro Activity of the Tigecycline, a New Glycylcycline, Tested against 1,326 Clinical Bacterial Strains Isolated from the Latin American Region, Lead author: Gales AC, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Enhanced Activity of Sitafloxacin against a Large Collection of Gram-positive Isolates From Latin America, Lead author: Andrade SS, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

In Vitro Activity of Omiganan (OMI) Pentahydrochloride, a Topical Cationic Peptide, Tested Against Contemporary Bacteria and Yeast Isolates, Lead author: Sader HS, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Contemporary In Vitro Synergy Rates for Aztreonam Combined with Newer Fluoroquinolones (FQ) and Beta-Lactams Tested Against Gram-Negative Bacilli, Lead author: Jones RN, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Worldwide Assessment of Dalbavancin (BI397) Activity and Spectrum (2002), Lead author: Stephen J, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Doripenem (S-4661), A Novel Carbapenem: Comparative Activity Against Contemporary Pathogens Including Anaerobes, Bactericidal Action and Methods Evaluations, Lead author: Jones RN, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Doripenem (S-4661), Antimicrobial Activity Tested Against Drug-Resistant Pathogens, Lead author: Huynh H, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

LB11058, a Novel Cephalosporin, Tested Against Neisseria gonorrhoeae Including Drug-Resistant Pathogens, Lead author: Jones RN, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Antimicrobial Activity of LB11058, A Novel Cephalosporin, Tested Against Staphylococci, Streptococci and Enterococci, Lead author: Sader HS, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Antimicrobial Activity of LB11058 Tested Against S. pneumoniae, H. influenzae and M. catarrhalis, Lead author: Johnson DM, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Relationship Between Increased Levofloxacin (LEV) Use and Decreased Susceptibility of Streptococcus pneumoniae (SP): Report From the ARREST Program, Lead author: Bhavnani SM, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Risk Assessment of Macrolide Use in Fed Cattle on the Treatment of Human Food-borne Illness, Lead author: Hurd HS, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Experience with ESBL-Producing Enterobacteriaceae (ENT) Treated with Carbapenems Compared to Other Beta-Lactams: Outcomes Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Jones RN, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

The Emergence of the Extended-Spectrum Beta-Lactamase GES-1 in a Pseudomonas aeruginosa strain in Brazil: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Gales AC, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

In Vitro Susceptibilities of Bloodstream Isolates of Rare Candida Species Against Ravuconazole and Three Licensed Antifungal Agents, Lead author: Pfaller MA, presented at 43rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 14 – 17, 2003, Chicago, Illinois

Antimicrobial Susceptibility Patterns for Pathogens Isolated from Pneumonia Patients in Latin American Medical Centers: Analysis from Five Years of the SENTRY Antimicrobial Surveillance Program, Lead author: Gales AC, presented at 103rd annual American Society for Microbiology General Meeting (ASM), May 18 – 22, 2003, Washington, DC

Re-Evaluations of the NCCLS Quality Control (QC) Guidelines for Gatifloxacin and Garenoxacin (BMS284756) When Susceptibility Testing H. influenzae and S. Pneumoniae, Lead author: Biedenbach DJ, presented at 103rd annual American Society for Microbiology General Meeting (ASM), May 18 – 22, 2003, Washington, DC

Initial Quality Control Guidelines for MIC Susceptibility Testing for NVP-LBM415, A Novel Peptide Deformylase Inhibitor, Lead author: Anderegg T, presented at 103rd annual American Society for Microbiology General Meeting (ASM), May 18 – 22, 2003, Washington, DC

Multicenter Quality Control Evaluation Results for Dalbavancin (BI397), An Investigational Glycopeptide With Potent Gram-Positive Activity, Lead author: Rhomberg PR, presented at 103rd annual American Society for Microbiology General Meeting (ASM), May 18 – 22, 2003, Washington, DC

Activity of Mupirocin Tested Against Staphylococci Isolated in Latin American Medical Centers: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Sader HS, presented at 103rd annual American Society for Microbiology General Meeting (ASM), May 18 – 22, 2003, Washington, DC

Antimicrobial Susceptibility of Bacteria Isolated from Blood Stream Infections (BSI) in Two Argentinean Medical Centers: Results from the SENTRY Antimicrobial Surveillance Program (1997-2001), Lead author: Smayevsky J, presented at 103rd annual American Society for Microbiology General Meeting (ASM), May 18 – 22, 2003, Washington, DC

Antagonism (ANTAG) Between Penicillin and Erythromycin Against Streptococcus pneumoniae: Does It Exist?, Lead author: Jones RN, presented at 103rd annual American Society for Microbiology General Meeting (ASM), May 18 – 22, 2003, Washington, DC

Clonal Dissemination and Expansion of Extended Spectrum beta-Lactamase (ESBL) Producing K. Pneumoniae in a Large Metropolitan Teaching Hospital: An Epidemiologic History from the SENTRY Antimicrobial Surveillance Program, Lead author: Dipersio J, presented at 103rd annual American Society for Microbiology General Meeting (ASM), May 18 – 22, 2003, Washington, DC

Relationships between susceptibility of Enterobacter spp. and hospital- and patient-specific variables. Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program), Lead author: Bhavnani SM, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Relationships between susceptibility of Streptococcus pneumoniae and hospital- and patient-specific variables. Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program), Lead author: Bhavnani SM, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Relationships between susceptibility of Pseudomonas aeruginosa and hospital- and patient-specific variables. Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program), Lead author: Bhavnani SM, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Antimicrobial usage and resistance trend comparisons from the MYSTIC Programme in North America (1999-2001), Lead author: Mutnick A, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Comparative antimicrobial potency and spectrum of activity for meropenem and nine comparator agents: Report from the United States MYSTIC Programme surveillance study in 2002, Lead author: Rhomberg PR, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

VIM-1 or VIM-1 + VIM-2 metallo-lactamase-producing Pseudomonas aeruginosa isolated from hospitalized children in Poland (1997-2002), Lead author: Patzer J, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Epidemiology and frequency of antimicrobial resistances among pathogens causing surgical site infections: Report from the SENTRY Antimicrobial Surveillance Program in United States, Canada, and Europe, Lead author: Mathai D, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Characterization of antimicrobial susceptibility patterns among community-acquired isolates of beta-haemolytic streptococci in Latin America: Results from the SENTRY Antimicrobial Surveillance Program (2001), Lead author: Gales AC, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Contemporary activity of grepafloxacin: Re-evaluation of antimicrobial features of a potent fluoroquinolone, Lead author: Jones RN, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Comparative activity of Garenoxacin against ciprofloxacin-susceptible and resistant Streptococcus pneumoniae isolates: Report from the SENTRY Antimicrobial Surveillance Programm (Europe, 1999-2001), Lead author: Canton R, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Initial description of the L22 mutation responsible for quinupristin/dalfopristin resistance in Streptococcus pneumoniae: Case Reports from the SENTRY Antimicrobial Surveillance Program, Lead author: Jones RN, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Cloning of a hybrid metallo-beta-lactamase gene conferring a novel IMP variant blaIMP-13 in Pseudomonas aeruginosa in Italy: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Toleman MA, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Species distribution and antifungal susceptibility patterns for Candida isolates from the SENTRY Antimicrobial Surveillance Program (Europe), Lead author: Prodhom G, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Prevalence and resistance rates of Enterobacter spp. in nosocomial infections, Euro-SENTRY Antimicrobial Surveillance program, 1997-2001, Lead author: Rodriguez-Villalobos H, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Evolution of an integron carrying blaVIM-2 in Central Europe: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Toleman MA, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Epidemiology of the new metallo-beta-lactamase gene, blaSPM, in South America: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Toleman MA, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Analysis of the blaVIM gene context from Italy reveals novel resistant cassettes: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Toleman MA, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens from intensive care units in Latin American medical centers: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Sader HS, presented at 13th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2003, Glasgow, Scotland

Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone. by Anderegg TR, Jones RN, The Quality Control Study Group published in Diagn. Microbiol. Infect. Dis. 2003; 45 (1): 73-76

Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans. by Yamazumi T, Pfaller MA, Messer SA, Houston AK, Boyken L, Hollis RJ, Furuta I, Jones RN published in J. Clin. Microbiol. 2003; 41 (1): 267-272

In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. by Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN and International Fungal Surveillance Participant Group published in J. Clin. Microbiol. 2003; 41 (1): 78-83

Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team. by Jones RN, Rubino CM, Bhavnani SJ and Ambrose PG published in Antimicrob. Agents Chemother. 2003; 47 (1): 292-296

CANCER Resistance Surveillance Program: initial results from hematology-oncology centers in North America. by Mutnick AH, Kirby JT, Jones RN and CANCER Study Group published in Ann. Pharmacol. 2003; 37 (1): 47-56